Back to Journals » Nature and Science of Sleep » Volume 7

Unmet needs of patients with narcolepsy: perspectives on emerging treatment options

Authors Wozniak D, Quinnell T

Received 2 February 2015

Accepted for publication 25 March 2015

Published 22 May 2015 Volume 2015:7 Pages 51—61

DOI https://doi.org/10.2147/NSS.S56077

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Steven A Shea


Dariusz R Wozniak, Timothy G Quinnell

Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK

Abstract: The treatment options currently available for narcolepsy are often unsatisfactory due to suboptimal efficacy, troublesome side effects, development of drug tolerance, and inconvenience. Our understanding of the neurobiology of narcolepsy has greatly improved over the last decade. This knowledge has not yet translated into additional therapeutic options for patients, but progress is being made. Some compounds, such as histaminergic H3 receptor antagonists, may prove useful in symptom control of narcolepsy. The prospect of finding a cure still seems distant, but hypocretin replacement therapy offers some promise. In this narrative review, we describe these developments and others which may yield more effective narcolepsy treatments in the future.

Keywords: cataplexy, hypocretin, H3 antagonist, GABA-B agonists, immunotherapy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]